Source - RNS
RNS Number : 6541U
Sportech PLC
16 July 2018
 

For immediate release

16 July 2018

 

 

Sportech PLC

 

('Sportech' or the 'Group')

 

Change of Date of Interim Results

 

 

Sportech PLC will announce its Interim Results for the half year ended 30 June 2018 on Wednesday 22 August 2018 rather than on Thursday 23 August 2018 as previously announced.

An analyst briefing will be given by the executive management team at 09.30hrs on Wednesday 22 August 2018 at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.

 

 

Contacts:

Sportech PLC

Tel: +44 (0)20 7268 2400

Andrew Gaughan, Chief Executive Officer

Tom Hearne, Chief Financial Officer

 

 

Buchanan

Tel: +44 (0) 20 7466 5000

(Financial PR adviser to Sportech)

Henry Harrison-Topham 

Mark Court

Tilly Abraham

[email protected]

 

Notes to Editors

 

About Sportech

Sportech PLC, listed on the London Stock Exchange, provides and operates technology solutions for some of the world's best-known gaming companies, sports teams, horse and greyhound racetracks, as well as owning and operating its own gaming venues in Connecticut, USA under exclusive licences.

 

The Group is an international betting technology business focused on highly regulated markets worldwide.  It has more than 27,000 betting terminals deployed to over 400 clients, across 37 countries including those in the USA, where it operates under 35 licences, across 37 States and processes approximately US$12 billion of bets annually.  The Group has invested over US$60 million in developing its technology services to clients and the successful expansion of its leading US gaming Venues in the last five years, resulting in its proprietary Quantum™ product being the most widely deployed pari-mutuel betting system globally.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOREXLFFVDFEBBX